JP2012525362A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012525362A5 JP2012525362A5 JP2012507808A JP2012507808A JP2012525362A5 JP 2012525362 A5 JP2012525362 A5 JP 2012525362A5 JP 2012507808 A JP2012507808 A JP 2012507808A JP 2012507808 A JP2012507808 A JP 2012507808A JP 2012525362 A5 JP2012525362 A5 JP 2012525362A5
- Authority
- JP
- Japan
- Prior art keywords
- cis
- product according
- pharmaceutical product
- trans
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000825 pharmaceutical preparation Substances 0.000 claims 10
- 229940127557 pharmaceutical product Drugs 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 6
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 4
- -1 C 2 -C 4 haloalkenyl Chemical group 0.000 claims 3
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 3
- 125000001931 aliphatic group Chemical group 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 210000005036 nerve Anatomy 0.000 claims 3
- 208000033808 peripheral neuropathy Diseases 0.000 claims 3
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims 2
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 2
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 208000028389 Nerve injury Diseases 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000002837 carbocyclic group Chemical group 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000006870 function Effects 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 229940126601 medicinal product Drugs 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000008764 nerve damage Effects 0.000 claims 2
- 230000003287 optical effect Effects 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 230000035807 sensation Effects 0.000 claims 2
- 239000012453 solvate Chemical class 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- GBXQPDCOMJJCMJ-UHFFFAOYSA-M trimethyl-[6-(trimethylazaniumyl)hexyl]azanium;bromide Chemical compound [Br-].C[N+](C)(C)CCCCCC[N+](C)(C)C GBXQPDCOMJJCMJ-UHFFFAOYSA-M 0.000 claims 2
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 1
- 206010006784 Burning sensation Diseases 0.000 claims 1
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims 1
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 1
- 208000004044 Hypesthesia Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 201000001880 Sexual dysfunction Diseases 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000003302 alkenyloxy group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 210000003423 ankle Anatomy 0.000 claims 1
- 210000000467 autonomic pathway Anatomy 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 201000003146 cystitis Diseases 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000002173 dizziness Diseases 0.000 claims 1
- 201000006549 dyspepsia Diseases 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 208000034783 hypoesthesia Diseases 0.000 claims 1
- 201000001881 impotence Diseases 0.000 claims 1
- 210000002414 leg Anatomy 0.000 claims 1
- 210000003141 lower extremity Anatomy 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 230000001537 neural effect Effects 0.000 claims 1
- 230000007658 neurological function Effects 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 231100000862 numbness Toxicity 0.000 claims 1
- 230000011514 reflex Effects 0.000 claims 1
- 230000001953 sensory effect Effects 0.000 claims 1
- 231100000872 sexual dysfunction Toxicity 0.000 claims 1
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 1
- 210000000689 upper leg Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0907601.9 | 2009-05-01 | ||
| GBGB0907601.9A GB0907601D0 (en) | 2009-05-01 | 2009-05-01 | Novel methods |
| PCT/GB2010/000817 WO2010125330A1 (en) | 2009-05-01 | 2010-04-22 | Use of pufas to treat nerve damage |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012525362A JP2012525362A (ja) | 2012-10-22 |
| JP2012525362A5 true JP2012525362A5 (enExample) | 2013-12-26 |
| JP5608220B2 JP5608220B2 (ja) | 2014-10-15 |
Family
ID=40792178
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012507808A Expired - Fee Related JP5608220B2 (ja) | 2009-05-01 | 2010-04-22 | 神経損傷の治療を目的としたｐｕｆａの使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20120122982A1 (enExample) |
| EP (1) | EP2424519A1 (enExample) |
| JP (1) | JP5608220B2 (enExample) |
| KR (1) | KR101664518B1 (enExample) |
| CN (1) | CN102448453B (enExample) |
| AU (1) | AU2010243368C1 (enExample) |
| BR (1) | BRPI1009922A2 (enExample) |
| CA (1) | CA2762009C (enExample) |
| GB (1) | GB0907601D0 (enExample) |
| MX (1) | MX2011011615A (enExample) |
| NZ (1) | NZ596674A (enExample) |
| SG (1) | SG175848A1 (enExample) |
| WO (1) | WO2010125330A1 (enExample) |
| ZA (1) | ZA201108571B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0907413D0 (en) | 2009-04-29 | 2009-06-10 | Equateq Ltd | Novel methods |
| US8293790B2 (en) | 2011-10-19 | 2012-10-23 | Dignity Sciences Limited | Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof |
| WO2015071766A1 (en) * | 2013-11-15 | 2015-05-21 | Dignity Sciences Limited | Pharmaceutically acceptable salts of polyunsaturated hydroxy fatty acids |
| US20210315851A1 (en) | 2020-04-03 | 2021-10-14 | Afimmune Limited | Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE10940T1 (de) * | 1981-05-12 | 1985-01-15 | Imperial Chemical Industries Plc | Pyrrolderivate. |
| US4532254A (en) * | 1983-03-17 | 1985-07-30 | Kaken Pharmaceutical Co., Ltd. | Inhibitor of aldose reductase |
| KR910005856B1 (ko) * | 1987-09-16 | 1991-08-05 | 다이호야꾸힝고오교가부시끼가이샤 | 티에노피리미딘 유도체 |
| DE69433713T2 (de) * | 1993-06-09 | 2005-04-07 | Martek Biosciences Corp. | Für die behandlung neurologischer erkrankungen nützliche methoden und pharmazeutische zusammensetzungen |
| US7015249B1 (en) * | 1997-12-12 | 2006-03-21 | Purdue Research Foundation | Methods and compositions for treating diabetes |
| US6107349A (en) * | 1998-04-16 | 2000-08-22 | Mantynen; Philip R. | Method and composition for treating psoriasis |
| GB9827391D0 (en) * | 1998-12-11 | 1999-02-03 | Fundation O N C F | Aldose reductase inhibitors and pharmaceutical compositions |
| CA2304906A1 (en) * | 2000-04-07 | 2001-10-07 | 1411198 Ontario Limited | 13-hode, a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia |
| CZ20023562A3 (cs) * | 2000-04-28 | 2003-03-12 | Sankyo Company, Limited | PPAR gama modulátory |
| EP1236720B1 (en) * | 2001-02-28 | 2005-06-15 | Pfizer Products Inc. | Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors |
| AU2002304931A1 (en) * | 2001-06-08 | 2002-12-23 | University Of British Columbia | Methods for treating disorders of the nervous and reproductive systems |
| CA2480429C (en) * | 2002-03-25 | 2008-09-16 | Biosynergen, Inc. | Novel therapeutical use of agonist ligands specific to g2a receptor |
| JP4972745B2 (ja) * | 2005-06-22 | 2012-07-11 | 国立大学法人群馬大学 | Ｇタンパク質共役型受容体ｇ２ａの作動薬、及びｇ２ａ活性調節薬のスクリーニング方法 |
| JP5366211B2 (ja) * | 2007-12-18 | 2013-12-11 | 国立大学法人富山大学 | アルドース還元酵素阻害活性を有する縮合三環化合物 |
-
2009
- 2009-05-01 GB GBGB0907601.9A patent/GB0907601D0/en not_active Ceased
-
2010
- 2010-04-22 CA CA2762009A patent/CA2762009C/en not_active Expired - Fee Related
- 2010-04-22 AU AU2010243368A patent/AU2010243368C1/en not_active Ceased
- 2010-04-22 NZ NZ596674A patent/NZ596674A/xx not_active IP Right Cessation
- 2010-04-22 JP JP2012507808A patent/JP5608220B2/ja not_active Expired - Fee Related
- 2010-04-22 KR KR1020117028669A patent/KR101664518B1/ko not_active Expired - Fee Related
- 2010-04-22 MX MX2011011615A patent/MX2011011615A/es active IP Right Grant
- 2010-04-22 EP EP10717725A patent/EP2424519A1/en not_active Withdrawn
- 2010-04-22 WO PCT/GB2010/000817 patent/WO2010125330A1/en not_active Ceased
- 2010-04-22 CN CN201080023442.8A patent/CN102448453B/zh not_active Expired - Fee Related
- 2010-04-22 BR BRPI1009922A patent/BRPI1009922A2/pt not_active IP Right Cessation
- 2010-04-22 US US13/318,420 patent/US20120122982A1/en not_active Abandoned
- 2010-04-22 SG SG2011080280A patent/SG175848A1/en unknown
-
2011
- 2011-11-22 ZA ZA2011/08571A patent/ZA201108571B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024050527A5 (enExample) | ||
| RU2014131014A (ru) | Димерные соединения-агонисты рецептора fgf (fgfr), способ их получения и их терапевтическое применение | |
| RU2016137678A (ru) | Соединения с эфирными группами для лечения опосредованных комплементом нарушений | |
| RU2013155586A (ru) | [1,3]оксазины | |
| AR063872A1 (es) | Derivados de acetileno como inhibidores de estearoil coa desaturasa | |
| RU2016103139A (ru) | Новые композиции для предупреждения и/или лечения лизосомных болезней накопления | |
| RU2009102278A (ru) | Модуляторы рецептора s1p для лечения рассеянного склероза | |
| RU2008107733A (ru) | Ингибиторы gsk-3 | |
| AU2014367781B2 (en) | Therapeutic and/or preventive agent comprising 1-indansulfamide derivative for pain | |
| RU2017116196A (ru) | 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 | |
| RU2019141734A (ru) | Терапевтические соединения и композиции и способы их применения | |
| RU2013130878A (ru) | Гидроксилированные производные аминотриазола в качестве агонистов рецептора alx | |
| JP2015535247A5 (enExample) | ||
| JP2012525362A5 (enExample) | ||
| JP2015502371A5 (enExample) | ||
| JP2012510985A5 (enExample) | ||
| RU2008141907A (ru) | Конъюгированные липидные производные | |
| RU2009128968A (ru) | Производные изосорбидмононитрата для лечения повышенной внутриглазной гипертензии | |
| JP5959083B2 (ja) | （１Ｒ−ｔｒａｎｓ）−Ｎ−［［２−（２，３−ジヒドロ−４−ベンゾフラニル）シクロプロピル］メチル］プロパンアミドの代謝物 | |
| AU2013253409A1 (en) | Analgesic | |
| KR20160005356A (ko) | 방사선완화 약제학적 제형 | |
| RU2007128080A (ru) | Производные пирролидиния в качестве мускариновых рецепторов мз | |
| CA2762009C (en) | Use of pufas to treat nerve damage | |
| JP2014510022A5 (enExample) | ||
| RU2011131855A (ru) | Новые оксимовые производные 3,5-секо-4-нор-холестана, фармацевтические композиции, содержащие их, и способ из получения |